ZVRA · NASDAQ · Biotechnology

Zevra Therapeutics (ZVRA)

Commercializes U.S.-approved therapies for Niemann-Pick type C disease and certain urea-cycle disorders.

$11.27
vs last close−0.31 (−2.68%)